BioLineRx (BLRX) Retained Earnings: 2023-2025
Historic Retained Earnings for BioLineRx (BLRX) over the last 2 years, with Jun 2025 value amounting to -$398.6 million.
- BioLineRx's Retained Earnings fell 2.00% to -$398.6 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$398.6 million, marking a year-over-year decrease of 2.00%. This contributed to the annual value of -$400.0 million for FY2024, which is 2.40% down from last year.
- Latest data reveals that BioLineRx reported Retained Earnings of -$398.6 million as of Q2 2025, which was down 1.00% from -$394.7 million recorded in Q1 2025.
- In the past 5 years, BioLineRx's Retained Earnings registered a high of -$342.2 million during Q1 2023, and its lowest value of -$400.0 million during Q4 2024.
- Over the past 3 years, BioLineRx's median Retained Earnings value was -$391.1 million (recorded in 2024), while the average stood at -$384.2 million.
- Data for BioLineRx's Retained Earnings shows a maximum YoY declined of 14.36% (in 2024) over the last 5 years.
- Over the past 3 years, BioLineRx's Retained Earnings (Quarterly) stood at -$390.6 million in 2023, then declined by 2.40% to -$400.0 million in 2024, then declined by 2.00% to -$398.6 million in 2025.
- Its last three reported values are -$398.6 million in Q2 2025, -$394.7 million for Q1 2025, and -$400.0 million during Q4 2024.